Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: Implication for simeprevir usage

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2024-2027

  Vidãl, Luãnna L ^a   Santos, André F ^a   Soares, Marcelo A ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

80R; Genotyping; PIs; Protease inhibitors

Indexed keywords

MONTIRELIN; SIMEPREVIR;

ARTICLE; CENTRAL AMERICA; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PHYLOGENY; PREVALENCE; SEQUENCE ALIGNMENT; SOUTH AMERICA; WESTERN EUROPE;

EID: 84936936737     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv081     Document Type: Article

References (19)

1. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 Suppl 1: 80-4.
2. Lenz O, de Bruijne J, Vijgen L et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology 2012; 143: 1176-8.e1-6.
3. Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-87.
4. Lagacé L, White PW, Bousquet C et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 2012; 56: 569-72.
5. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3.
6. Jacobson IM, Dori GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
7. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
8. US FDA. Olysio (Simeprevir) for the Treatment of Chronic Hepatitis C in Combination Antiviral Treatment. http://www.fda.gov/forpatients/illness/hepatitisbc/ucm377234.htm.
9. EMA. Olysio-Simeprevir. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002777/human_med_001766. jsp&mid=WC0b01ac058001d124.
10. Kieffer TL, De Meyer S, Bartels DJ et al. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012; 7: e34372.
11. Lisboa-Neto G, Noble CF, Pinho JR et al. Resistancemutations are rare among protease inhibitor treatment-naive hepatitis C genotype 1 patients with or without HIV coinfection. Antivir Ther 2014; doi:10.3851/ IMP2873.
12. de Carvalho IM, Alves R, de Souza PA et al. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches. J Med Virol 2014; 86: 1714-21.
13. Morel V, Duverlie G, Brochot E. Patients eligible for treatment with simeprevir in a French center. J Clin Virol 2014; 61: 149-51.
14. Palanisamy N, Danielsson A, Kokkula C et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013; 99: 12-7.
15. Andonov A, Kadkhoda K, Osiowy C et al. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Can J Gastroenterol 2013; 27: 414-6.
16. Larkin MA, Blackshields G, Brown NP et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-8.
17. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Sympos Ser 1999; 41: 95-8.
18. Pereira LM, Martelli CM, Moreira RC et al. Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 2013; 13: 60.
19. Poveda E, Wyles DL, Mena A et al. Update on hepatitis Cvirus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-91.